In the last four decades, nanotechnology has gained momentum with no sign of slowing
down. The application of inventions or products from nanotechnology has revolutionised all …

Antibody therapies have become an important class of therapeutics in recent years as they
have exhibited outstanding efficacy and safety in the treatment of several major diseases …

The modification of proteins with non‐protein entities is important for a wealth of
applications, and methods for chemically modifying proteins attract considerable attention …

Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R)
monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic …

Rheumatoid arthritis (RA) is a debilitating autoimmune disease with grave physical,
emotional and socioeconomic consequences. Despite advances in targeted biologic and …

The use of proteins as therapeutics has a long history and is becoming ever more common
in modern medicine. While the number of protein-based drugs is growing every year …

There is considerable interest in the pharmaceutical industry toward development of
antibody-based biotherapeutics because they can selectively bind diverse receptors and …

Polymer conjugation is an efficient approach to improve the delivery of drugs and biological
agents, both by protecting the body from the drug (by improving biodistribution and reducing …

Monoclonal antibodies (mAbs) are one of the most important classes of therapeutic proteins,
which are used to treat a wide number of diseases (eg, oncology, inflammation and …

Background To date, head-to-head trials comparing the efficacy and safety of biological
disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in …